A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
← catalyst calendarNCT06487559 · readout ≤ 192 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
3actual
Sites
11
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-11 | actual | When the study began enrolling |
| Primary completion | Feb 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-07-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hepatocellular Carcinoma (HCC)
Interventions
- Drug: Livmoniplimab — also filed as ABBV-151
- Drug: Budigalimab — also filed as ABBV-181
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants With Adverse Events (AE)
measured Up to Approximately 2 Years
Number of Participants with Dose-Limiting Toxicities (DLT)
measured Up to Approximately 2 Years
Maximum Plasma Concentration (Cmax) of Livmoniplimab and Budigalimab
measured Up to Approximately 2 Years
Area Under the Serum Concentration Versus Time Curve (AUC) of Livmoniplimab and Budigalimab
measured Up to Approximately 2 Years
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed